Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Join us! Registration is OPEN for the 2023 English Targeted Therapies Patient Forum!
Author
Denise Brock
Image
TTF 2023 English header

Join us on SATURDAY, JULY 15th, 2023, for the 2023 Targeted Therapies Patient Forum

This virtual program is presented Live Online from 10 AM - 4 PM EDT

Register Now! 

In this 9th annual live patient forum, leading thoracic oncologists from around the world as well as lung cancer patients who are active within the patient advocacy community discuss subjects relevant to all targets as well as breakout sessions on rare mutations.

 

This 6-hour live virtual webinar is an opportunity for lung cancer patients and caregivers to hear from experts and participate in live virtual Q&A sessions.  The forum offers panel discussions, live Q&A sessions, and breakout sessions focused on rare mutations such as EGFR, ALK, ROS, RET and KRAS.  This event is free but registration is required and limited.  For more information visit the full AGENDAFaculty Bio's willl be available soon. 

2023 Targeted Therapies in Lung Cancer Patient Forum

***Subject to Change***

Event Chairs:   Sandip Patel, MD, Jessica Lin, MD

Topics include:

  • Biomarker Testing: The Fundamentals and The Challenges
  • Non-Metastatic Disease and Targeted Therapies
  • After or Adding To Targeted Therapy
  • Patient and Research Advocacy Presentation
  • Resistance Mechanisms and Re-Biopsies
  • Symptom Management and Palliative Care

   Breakout Session Rooms will include the following discussions:

  • EGFR
  • EGFR Ex 20, HER 2
  • ALK, ROS 1 
  • RET, Rare Fusions
  • KRAS
  • MET, BRAF

Each session includes full Panel Discussions and Q&A Sessions.  View the full AGENDA here. 


 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora